Aclaris Therapeutics (ACRS) Tops Q2 EPS by 3c, misses on revenue

Aclaris Therapeutics (NASDAQ: ACRS) reported Q2 EPS of ($0.42), $0.03 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $1.87 million versus the consensus estimate of $1.9 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance